RCT-DUPLICATE Findings Demonstrate Capability of Real-World Evidence Studies to Reach Conclusions Similar to Randomized Clinical Trials

NEW YORK, April 25, 2023 /PRNewswire/ -- Aetion®, the global leader in real-world evidence (RWE) technology and analytics, is pleased to announce the culmination of the RCT-DUPLICATE demonstration project, with complete findings published today in The Journal of the American Medical Association (JAMA). This three-year initiative tested whether researchers asking clinical questions in real-world data (RWD) — data from patients' day-to-day interactions with the healthcare system — would obtain similar results to findings from randomized clinical trials (RCTs). In cases where clinical trial designs aligned with real patient care processes, the RWE studies and RCTs came to largely similar conclusions.

As part of the RCT-DUPLICATE initiative, researchers created and published protocols for observational, real-world analogs to thirty completed and two ongoing RCTs, emulating each trial's design as closely as possible. They then implemented the studies principally using the Aetion Evidence Platform® (AEP), which analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on the safety, effectiveness, and value of medical treatments.

The results show that in about half of the cases where researchers were able to closely mimic the design of the corresponding RCT using RWD, the RWE study came to a similar conclusion as the analogous RCT. In many cases where RWE and RCTs did not come to a similar conclusion, the RCT design itself did not align with real-world clinical practice, creating a challenge for emulation of the trial using RWD. In these instances, RWE and RCTs may both be reaching meaningful conclusions, but to subtly different research questions.

"The RCT-DUPLICATE initiative further demonstrates that RWE has the potential to augment findings from RCTs and guides us to cases where RWE and RCTs may be expected to reach similar conclusions," said Nicolle Gatto, Ph.D., M.P.H., Chief Science Officer at Aetion. "This work is important in promoting and understanding the value of RWE for decision-making as we continue to assess RWE's uses, benefits, and limitations."

Today's publication, alongside ongoing research like the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative and other demonstration projects, adds to a body of evidence that demonstrates how RWE can be relied on to broaden our understanding of the safety, effectiveness, and value of medications — complementing or extending what can be demonstrated by RCTs.

To learn more about how RCT-DUPLICATE advances RWE, visit JAMA. 

About Aetion®
Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us on LinkedIn.

SOURCE Aetion